The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine

Pharmacotherapy

Volumn 20, Issue 5, 2000, Pages 549-553

  Piscitelli, Stephen C ^a,d   Kress, Diane Rock ^b   Bertz, Richard J ^c   Pau, Alice ^a   Davey, Richard ^b  

^a Laboratory of Immunoregulation   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c ABBOTT LABORATORIES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORPETHIDINE; PETHIDINE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SCREENING; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER METABOLISM; MALE; NEUROTOXICITY; NORMAL HUMAN;

EID: 0034024545     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.6.549.35162     Document Type: Article

References (16)

1. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.
2. Abbott Laboratories. Norvir (ritonavir) package insert. Abbott Park, IL; 1998.
3. Meatherall RC, Guay DR, Chalmers JL. Analysis of meperidine and normeperidine in serum and urine by high-performance liquid chromatography. J Chromatogr. 1985;338:141-9.
4. Danner S, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
5. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998;63:453-64.
6. Ouellet D, Hsu A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1998;64:355-62.
7. Cato A III, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998;63(4):414-21.
8. Hsu A, Granneman GR, Carothers L, et al. Ritonavir does not increase methadone exposure in healthy volunteers [abstr]. Abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
9. Guibert A, Furlan V, Martino J, Taburet AM. In vitro effect of HIV protease inhibitors on methadone metabolism [abstr]. Abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Canada, September 28-October 1, 1997.
10. Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-91.
11. Hsu A, Granneman GR, Witt G, et al Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 1997;41:898-905.
12. Pond SM, Kretschzmar KM. Effect of phenytoin on meperidine clearance and normeperidinc formation. Clin Pharmacol Ther 1981;30:680-6.
13. Slambaugh JE, Wainer IW, Schwartz IRA. The effect of phenobarbital on the metabolism of meperidine in normal volunteers. J Clin Pharmacol 1978;18:482-90.
14. Guay DRP, Meatherall RC, Chalmers JL, Grahame GR. Cimetidinc alters pethidine disposition in man. Br J Clin Pharmacol 1984;18:907-14.
15. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J. HIV protease inhibitor ritonavir: a more potent inhibitor of p-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999;57:1147-52.
16. Armstrong PJ, Bersten A. Normeperidine toxicity. Anesth Analg 1980;65;536-8.